A clinical trial on the follow-up of nonalcoholic fatty liver disease: An evaluation of pathological endpoint

Jiang LiNa; Zhao JingMin

doi:10.3969/j.issn.1001-5256.2018.12.004

Issue 12

Dec. 2018

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2018 > 34(12): 2505-2508

PDF( 1615 KB)

A clinical trial on the follow-up of nonalcoholic fatty liver disease: An evaluation of pathological endpoint

DOI: 10.3969/j.issn.1001-5256.2018.12.004

Research funding:

Published Date: 2018-12-20

Abstract

Abstract

Liver biopsy is the“gold standard”for the diagnosis of nonalcoholic fatty liver disease (NAFLD) /nonalcoholic steatohepatitis (NASH) . Although liver biopsy has several limitations including invasiveness and errors in sampling and evaluation, in clinical trials on NAFLD/NASH follow-up and new drugs, liver histological evaluation is still a main and irreplaceable method for inclusion/exclusion diagnosis and assessment of primary endpoints in cohorts. It often takes 10-20 years for NASH to progress to liver cirrhosis, which is a surrogate endpoint in clinical trials for new drugs, and the NASH Clinical Research Network (NASH-CRN) system is recommended as the histological evaluation system in clinical trials for tracking NAFLD/NASH. The primary endpoint for NASH treatment is usually set as the reversal of NASH without progression of fibrosis; an alternative one is a reduction in NAS score by at least 2 points and a reduction in one or more histological parameters by at least 1 point, without progression of fibrosis, during the full-course treatment. Patients in phase 2 b and 3 clinical trials should be monitored for at least 12 months, and if the improvement of fibrosis is set as the main assessment index, they should be monitored for at least 1-2 years and should be followed up for more than 6 months after drug withdrawal. Histological evaluation is affected by various factors. In order to ensure the quality of such evaluation, the length of tissue for liver biopsy should be larger than 2 cm (containing more than 10 portal areas) . Staining and section preparation should be performed at the same time, and more than two experts specializing in liver pathology should perform single-or double-blinded review of liver biopsies to avoid evaluation bias.
- non-alcoholic fatty liver disease,
- liver cirrhosis,
- pathologic processes,
- biopsy, needle,
- clinical trial

FullText(HTML)

References(28)

References

[1] RINELLA ME. Nonalcoholic fatty liver disease:A systematic review[J]. JAMA, 2015, 313 (22) :2263-2273.

[2] DIEHL AM, DAY C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis[J]. N Engl J Med, 2017, 377 (21) :2063-2073.

[3] FAN JG, KIM SU, WONG VW. New trends on obesity and NAFLD in Asia[J]. J Hepatol, 2017, 67 (4) :862-873.

[4] ROTMAN Y, SANYAL AJ. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease[J]. Gut, 2017, 66 (1) :180-190.

[5] SANYAL AJ, BRUNT EM, KLEINER DE, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis[J]. Hepatology, 2011, 54 (1) :344-353.

[6] SANYAL AJ, FRIEDMAN SL, MCCULLOUGH AJ, et al. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis:Findings and recommendations from an American Association for the Study of Liver Diseases-U. S. Food and Drug Administration Joint Workshop[J]. Hepatology, 2015, 61 (4) :1392-1405.

[7] CAUSSY C, REEDER SB, SIRLIN CB, et al. Noninvasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials[J]. Hepatology, 2018, 68 (2) :763-772.

[8] NEUSCHWANDER-TETRI BA, LOOMBA R, SANYAL AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for noncirrhotic, non-alcoholic steatohepatitis (FLINT) :A multicentre, randomised, placebo-controlled trial[J]. Lancet, 2015, 385 (9972) :956-965.

[9] NALBANTOGLU IL, BRUNT EM. Role of liver biopsy in nonalcoholic fatty liver disease[J]. World J Gastroenterol, 2014, 20 (27) :9026-9037.

[10] VIOLI F, CANGEMI R. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis[J]. N Engl J Med, 2010, 363 (12) :1185-1186.

[11] FRIEDMAN S, SANYAL A, GOODMAN Z, et al. Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis:CENTAUR Phase 2b study design[J]. Contemp Clin Trials, 2016, 47:356-365.

[12] SANYAL AJ, MOFRAD PS, CONTOS MJ, et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis[J]. Clin Gastroenterol Hepatol, 2004, 2 (12) :1107-1115.

[13] NEUSCHWANDER-TETRI BA, BRUNT EM, WEHMEIER KR, et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone[J]. Hepatology, 2003, 38 (4) :1008-1017.

[14] BRUNT EM, JANNEY CG, DI BISCEGLIE AM, et al. Nonalcoholic steatohepatitis:A proposal for grading and staging the histological lesions[J]. Am J Gastroenterol, 1999, 94 (9) :2467-2474.

[15] KLEINER DE, BRUNT EM, van NATTA M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease[J]. Hepatology, 2005, 41 (6) :1313-1321.

[16] BEDOSSA P. FLIP Pathology Consortium. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease[J]. Hepatology, 2014, 60 (2) :565-575.

[17] BEDOSSA P, POITOU C, VEYRIE N, et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients[J]. Hepatology, 2012, 56 (5) :1751-1759.

[18] ALKHOURI N, de VITO R, ALISI A, et al. Development and validation of a new histological score for pediatric non-alcoholic fatty liver disease[J]. J Hepatol, 2012, 57 (6) :1312-1318.

[19] European Association for the Study of the Liver (EASL) ; European Association for the Study of Diabetes (EASD) ; European Association for the Study of Obesity (EASO) . EASL-EASD-EASD Clinical Practice Guidelines for the management of nonalcoholic fatty liver disease[J]. J Hepatol, 2016, 64 (6) :1388-1402.

[20] YOUNOSSI ZM, GRAMLICH T, LIU YC, et al. Nonalcoholic fatty liver disease:Assessment of variability in pathologic interpretations[J]. Mod Pathol, 1998, 11 (6) :560-565.

[21] BEDOSSA P, CARRAT F. Liver biopsy:The best, not the gold standard[J]. J Hepatol, 2009, 50 (1) :1-3.

[22] ROCKEY DC, CALDWELL SH, GOODMAN ZD, et al. Liver biopsy[J]. Hepatology, 2009, 49 (3) :1017-1044.

[23] LARSON SP, BOWERS SP, PALEKAR NA, et al. Histopathologic variability between the right and left lobes of the liver in morbidly obese patients undergoing Roux-en-Y bypass[J]. Clin Gastroenterol Hepatol, 2007, 5 (11) :1329-1332.

[24] YANG M, XU D, LIU Y, et al. Combined serum biomarkers in non-invasive diagnosis of non-alcoholic steatohepatitis[J]. PLo S One, 2015, 10 (6) :e0131664.

[25] YOUNOSSI ZM, LOOMBA R, ANSTEE QM. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis[J]. Hepatology, 2018, 68 (1) :349-360.

[26] CHEAH MC, MCCULLOUGH AJ, GOH GB. Current modalities of fibrosis assessment in non-alcoholic fatty liver disease[J]. J Clin Transl Hepatol, 2017, 5 (3) :261-271.

[27] MAIDA M, MACALUSO FS, SALOMONE F, et al. Non-invasive assessment of liver injury in non-alcoholic fatty liver disease:A review of literature[J]. Curr Mol Med, 2016, 16 (8) :721-737.

[28] VILAR-GOMEZ E, CHALASANI N. Non-invasive assessment of non-alcoholic fatty liver disease:Clinical prediction rules and blood-based biomarkers[J]. J Hepatol, 2018, 68 (2) :305-315.

Relative Articles

[1]	Wenjing NI, Nan GENG, Xue BAI, Jie LI. An excerpt of EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease in 2024[J]. Journal of Clinical Hepatology, 2024, 40(8): 1567-1574. doi: 10.12449/JCH240810
[2]	Xiaoyong DUO, Shijie ZHANG, Hongwei ZHANG, Jing YANG, Wenqiang WANG, Linzhi YU, Baocai ZHANG, Yicheng ZHUO, Yunchao JIA, Yan PENG, Shuai HU. Association between gallstones and metabolic syndrome in southern Xinjiang, China[J]. Journal of Clinical Hepatology, 2022, 38(8): 1859-1864. doi: 10.3969/j.issn.1001-5256.2022.08.026
[3]	CHEN Huan, LI Ting, WANG ZiJie, WANG ZhongQiong, LUO Gang, DENG MingMing. Influence of metabolic syndrome and its components on the prognosis of patients with pancreatic cancer[J]. Journal of Clinical Hepatology, 2020, 36(12): 2788-2794. doi: 10.3969/j.issn.1001-5256.2020.12.029
[4]	Tian Tian, Hu WenWei, Li Xue, Li Ji, Zhang Dan, Li ZhangZheng. Metabolic characteristics of nonalcoholic fatty liver disease and related risk factors in non-obese population[J]. Journal of Clinical Hepatology, 2020, 36(6): 1310-1313. doi: 10.3969/j.issn.1001-5256.2020.06.024
[5]	Niu ChunYan, Liu Qin, Luo XiaoChun. Reexamination of the diagnosis of fatty liver disease under the background of disease spectrum progression[J]. Journal of Clinical Hepatology, 2020, 36(10): 2356-2359. doi: 10.3969/j.issn.1001-5256.2020.10.043
[6]	Chinese Society of EndocrinologyChinese Medical Association. Consensus for diagnosis and treatment of nonalcoholic fatty liver diseases and metabolic disorders (2nd Edition)[J]. Journal of Clinical Hepatology, 2018, 34(10): 2103-2108. doi: 10.3969/j.issn.1001-5256.2018.10.010
[7]	Wu QiQi, Ma Yan, Wang XiaoBo, Xu Qiang, Wang Yan, Bai Li. Influence of metabolic syndrome on significant hepatic fibrosis in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2018, 34(12): 2572-2577. doi: 10.3969/j.issn.1001-5256.2018.12.013
[8]	Zhou BingBing, Wang XueMei, Zhang Qian, Xu ShiYi, Dan ZhongYan, Lai YaXin, Wang HaoYu. Association between metabolic syndrome and gallstones[J]. Journal of Clinical Hepatology, 2017, 33(5): 880-882. doi: 10.3969/j.issn.1001-5256.2017.05.017
[9]	Xu BeiBei, Wang BingYuan. Nonalcoholic fatty liver disease and serum uric acid[J]. Journal of Clinical Hepatology, 2016, 32(3): 437-441. doi: 10.3969/j.issn.1001-5256.2016.03.007
[10]	Li LiangPing. Nonalcoholic fatty liver disease and hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2016, 32(3): 432-436. doi: 10.3969/j.issn.1001-5256.2016.03.006
[11]	Fan JianGao, Yan ShiYan. Metabolic syndrome and fatty liver[J]. Journal of Clinical Hepatology, 2016, 32(3): 407-410. doi: 10.3969/j.issn.1001-5256.2016.03.001
[12]	Zhao HongXin, Yan Rong, Niu ChunYan, Zhou YongLi, Wang Jia, Cao RuiQi. Prevalence and associated risk factors for obesity and nonalcoholic fatty liver disease in adolescents in Xi′an, Shaanxi province, China[J]. Journal of Clinical Hepatology, 2015, 31(8): 1248-1251. doi: 10.3969/j.issn.1001-5256.2015.08.016
[13]	Huang Ying, Chen Hong. Research progress in association between nonalcoholic fatty liver disease and gallstone disease[J]. Journal of Clinical Hepatology, 2014, 30(11): 1217-1220. doi: 10.3969/j.issn.1001-5256.2014.11.033
[14]	Fan JianGao, Zhu ChanYan. Strengthening research on relationship between metabolic syndrome and chronic liver disease[J]. Journal of Clinical Hepatology, 2013, 29(12): 881-884. doi: 10.3969/j.issn.1001-5256.2013.12.001
[15]	Yan Jie, Xie Wen. Relationship between metabolic syndrome and chronic hepatitis C[J]. Journal of Clinical Hepatology, 2013, 29(12): 887-889. doi: 10.3969/j.issn.1001-5256.2013.12.003
[16]	Li LiangPing, Zhong Huang. The study of cytokeratin 18 fragments and inflammation related factors in non-alcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2012, 28(5): 359-363.
[17]	Zhang YiNing, Du HongWei, Liu YanJun, Wang ChaoXia. The diagnosis and risk factors for evaluation of nonalcoholic fatty liver disease in children and adolescents[J]. Journal of Clinical Hepatology, 2011, 27(7): 690-693.
[18]	Wu Tao, Yin ShouYi, Wang HongZhang, Zhang Hong, Jia Wei, Ji Guang. The clinical features and risk factors of patient with metabolic syndrome combined with non-alcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2011, 27(10): 1036-1040.
[19]	Ruan JianWen, Yang Jing, Gao LiJuan. Advances in the relationship between metabolic syndrome and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2011, 27(10): 1102-1105.
[20]	Niu ChunYan, Yan Rong, Tian Yu, Ma HuiXia, Jiao ShuJiang. The prevalence of fatty liver disease and its relationship with metabolic syndrome[J]. Journal of Clinical Hepatology, 2010, 26(2): 167-169.

Supplements(0)

Cited By

Cited by

Periodical cited type(3)

1.	梁海锋，梁国志，袁观斗，郭振亚，何松青. 小肝综合征的发病机制及防治研究进展. 中华实验外科杂志. 2024(03): 639-643 .
2.	蔡景治，郑扬，仲伟明，刘波. 基于Bcl-2/CytC探究槲皮素对肝硬化大鼠微循环及肝脏病变的影响. 现代生物医学进展. 2023(05): 818-823 .
3.	赵媛，赵明，范玉梅，邵建营. 失代偿期乙型肝炎肝硬化患者不同病毒学应答状态对生存率及肝癌患病率的影响. 中国实用医刊. 2020(23): 50-52 .

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2197) PDF downloads(406)

A clinical trial on the follow-up of nonalcoholic fatty liver disease: An evaluation of pathological endpoint

DOI: 10.3969/j.issn.1001-5256.2018.12.004